Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars-Reference-Cited by-同舟云学术

Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars

Published:2017-06-26 Issue:8 Volume:17 Page:915-926
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Inotai András¹²,Prins Christiaan P.J³,Csanádi Marcell¹,Vitezic Dinko⁴,Codreanu Catalin⁵,Kaló Zoltán¹²

Affiliation:

1. Syreon Research Institute, Budapest, Hungary

2. Department of Health Policy & Health Economics, Faculty of Social Sciences, Eötvös Loránd University (ELTE) Budapest, Hungary

3. Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands

4. University of Rijeka School of Medicine and University Hospital Centre Rijeka, Rijeka, Croatia

5. Center for Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania

Funder

Egis Pharmaceuticals PLC

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2017.1341486

Reference86 articles.

1. Biosimilars: Are They Bioequivalent?

2. Postmarket policy considerations for biosimilar oncology drugs

3. Current status of biosimilars in the treatment of inflammatory bowel diseases

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the Biosimilar Paradox of Oncologists’ Perceptions and Hesitations in South Korea: A Web-Based Survey Study;BioDrugs;2024-01-12

2. Impact of switching between reference biologics and biosimilars of tumour necrosis factor inhibitors for rheumatoid arthritis: a systematic review and network meta-analysis;Scientific Reports;2023-08-22

3. A Systematic Literature Review of Gaps and Challenges in Value Assessment of Biosimilars: An ISPOR Special Interest Group Report;Value in Health;2023-08

4. Maximizing the benefits of using biosimilars in Egypt;Journal of Pharmaceutical Policy and Practice;2023-06-26

5. Intercambialidade e aspectos farmacoeconômicos dos medicamentos biossimilares;JMPHC | Journal of Management & Primary Health Care | ISSN 2179-6750;2023-04-26